Precision Medicine Podcast · Trapelo

Part 1. The Alarming Rise of Colorectal Cancer: Advocate Trevor Maxwell Explains Why Basic Screening Is Mission Critical

·38 min·2 clips
A person born in 1990 has twice the colon-cancer risk and four times the rectal-cancer risk of someone born in 1950.
1. Precision Medicine Podcast focuses this episode on the rise of colorectal cancer and the screening gap around young-onset CRC. 2. Karen Cushman hosts and produces the show, and Trevor Maxwell joins as a stage 4 colorectal cancer patient, founder of Man Up to Cancer, journalist, and author of Open Heart, Warrior Spirit. 3. The episode asks what colorectal cancer screening should look like now, especially for people under 45 who are still being missed. 4. Cushman cites the American Cancer Society’s report that people over 50 now have a 50% greater chance of being diagnosed than they had in the 1990s. 5. Maxwell says he was diagnosed at age 41 and has lived with stage 4 colorectal cancer since March 2018. 6. He says young-onset CRC has become the leading cancer killer for men under 50 and the second leading cancer killer for women under 50. 7. Maxwell points to common screening tools such as colonoscopy, FIT testing, Cologuard, and newer blood tests like Shield from Guardant. 8. He says colonoscopy at age 45 remains the gold standard because it can find and remove precancerous polyps before cancer develops. 9. He says people are still waiting six, 12, or 18 months for colonoscopy appointments, which creates another barrier. 10. Maxwell argues that people under 45 have no routine screening protocol unless they already have symptoms or a family history. 11. He says many younger patients are told they are too young for CRC and are instead told it is hemorrhoids, mental health, or something less serious. 12. He says many of the younger people he has met are marathoners, swimmers, football players, or others who ate clean and still developed CRC. 13. Maxwell describes CRC as a disease that is highly treatable and highly curable in stages 1 through 3, with much worse outcomes at stage 4. 14. He says stage 4 CRC still has a five-year overall survival rate under 15%. 15. He explains that immunotherapy works best for a small MSI-high subset, while most CRC tumors are cold and do not respond well. 16. Maxwell says he is MSI-high and has Lynch syndrome, which helped him respond well to immunotherapy and later manage liver and peritoneal disease with other methods. 17. He says precision medicine access depends heavily on where a patient is treated, especially whether they are at an NCI center or a community practice. 18. The conversation is conversational and practical, with Cushman layering statistics and Maxwell answering with patient-level examples, advocacy advice, and direct language. 19. People following CRC screening, biomarkers, and patient advocacy will get the most from this episode. 20. Listeners wanting a light overview without cancer-care detail may skip it.

As heard by us

A steady, patient-centered discussion of colorectal cancer screening and treatment choices.

Precision Medicine Podcast centers on a guest who has lived with stage four colorectal cancer since March 2018 and has gone through surgery, chemotherapy, immunotherapy, and a clinical trial.

Read the full review in PlayNext →

Why you'd press play

Hear a patient leader unpack stage four colorectal cancer, the screening-age debate, and why early action still matters.

Read the full recommendation in PlayNext →
Listen to the show on